A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.

Tae Seo SohnKyung-Ah HanYonghyun KimByung-Wan Lee Suk Chon In-Kyung Jeong Eun Gyoung HongJang Won SonJaeJin NaJae Min ChoSeong In ChoWan HuhKun-Ho Yoon

Published in: Diabetes, obesity & metabolism (2024)

Enavogliflozin added to metformin was tolerated well for up to 52 weeks and provided continual glycaemic control in type 2 diabetes mellitus, along with a significant increase in the urine glucose-creatinine ratio.

Keyphrases

type diabetes
clinical trial
randomized controlled trial
metabolic syndrome
uric acid
blood glucose
insulin resistance
study protocol